The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - BioNTech (I); GANYMED Pharmaceuticals
Leadership - BioNTech (I); GANYMED Pharmaceuticals
Stock and Other Ownership Interests - BioNTech; BioNTech (I); GANYMED Pharmaceuticals
Consulting or Advisory Role - GANYMED Pharmaceuticals (I)
Patents, Royalties, Other Intellectual Property - BioNTech; BioNTech (I); GANYMED Pharmaceuticals; GANYMED Pharmaceuticals (I)
First-in-human phase I/II dose-escalation study of IMAB027 in patients with recurrent advanced ovarian cancer (OVAR): Preliminary data of phase I part.
 
Ugur Sahin
Employment - BioNTech; GANYMED Pharmaceuticals (I)
Leadership - BioNTech; GANYMED Pharmaceuticals (I)
Stock and Other Ownership Interests - BioNTech; GANYMED Pharmaceuticals (I)
Consulting or Advisory Role - GANYMED Pharmaceuticals
Patents, Royalties, Other Intellectual Property - BioNTech; BioNTech (I); GANYMED Pharmaceuticals; GANYMED Pharmaceuticals (I)
 
Dirk Jaeger
No Relationships to Disclose
 
Frederik Marme
No Relationships to Disclose
 
Athanasios Mavratzas
No Relationships to Disclose
 
Jürgen Krauss
Honoraria - Boehringer Ingelheim; Merck KGaA
Consulting or Advisory Role - Affitech AG
 
Jacques De Greve
Research Funding - Roche Pharma AG; Roche Pharma AG (Inst)
Travel, Accommodations, Expenses - Roche Pharma AG
 
Ignace Vergote
No Relationships to Disclose
 
Oezlem Tureci
No Relationships to Disclose